Jefferies analyst David Windley sees FDA approvals of GLP-1s...
Jefferies analyst David Windley sees FDA approvals of GLP-1s for obesity treatment as a huge opportunity for the manufacturing supply chain. He also notes high rivalry in the injectable fill/finish market. Windley upgraded West Pharmaceutical to Buy, raising its price target by 66% to $536, citing its global footprint and capacity to meet growing GLP-1s demand.
Booming Weight-loss Drug Market to Lift "pick-and-shovel" Plays: Jefferies
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment